返回排名列表

Henry Schein, Inc. (HSIC)

合理估值
HealthcareMedical DistributionUnited States

基本面

58

价格

$84.64

市值

$9.57B

第一部分 · 这家公司值多少

概览

Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as provides equipment repair services, financial services on a non-recourse basis, continuing education services for practitioners, consulting, and other services. It also markets and sells a portfolio of consumable merchandise under its own corporate brand. The Global Specialty Products segment engage in manufacturing, marketing, and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products, and other health care-related products and services. The Global Technology segment is involved in the development and distribution of practice management software, e-services, and other products which are distributed to health care providers. The company serves dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics, home health providers, and other alternate care clinics. It has a strategic partnership with GoTu Technology to help dental practices address ongoing staffing challenges. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

Compare

Generated on 2026年9月18日 with claude-haiku-4-5 — shared with all users

P/E: 22.9Score: 78Market cap: $99.84B

Cited by Henry Schein as one of two national competitors in medical distribution, McKesson supplies the same office-based physicians and alternate-care sites with pharmaceuticals and medical-surgical products.

P/E: 32.0Score: 76Market cap: $51.78B

Its Medical segment distributes surgical and examination supplies to physician offices, ambulatory surgery centers and home-care providers, the same alternate-care customers Henry Schein Medical serves.

Patterson Companies, Inc. (Patterson Dental)Not tracked

Named in Henry Schein's 10-K as its main U.S. rival, Patterson Dental sells the same consumables, equipment and practice-management software to the same dental offices, and has been privately held since Patient Square Capital took it off Nasdaq in April 2025.

Benco Dental Supply CompanyNot tracked

The third full-service dental distributor in the United States, family-owned and unlisted, competing with Henry Schein practice by practice for the same dental supply and equipment budgets.

Medline Industries, LPNot tracked

The other national medical competitor named in the 10-K, privately held, selling medical-surgical supplies to the same physician practices, surgery centers and long-term care facilities.

资产负债表与流动性

营收

$13.60B

最近12个月(截至2026/6/27)

净利润

$403M

最近12个月(截至2026/6/27)

自由现金流

$573M

股东权益合计

$3.25B

负债合计

$6.42B

流动比率

1.32

利息覆盖率

4.28

债务/EBITDA

3.96

每股收益

营收与净利润

自由现金流

收入构成

历史财务表

利润率变化

债务变化

债务负担有多重

增长一览表

增长 — 营业收入

公允价值估算

一般情形合理估值

公允价值

$77.47

当前价格

$84.64

安全边际

-9.2%

公允价值区间

$53.98 - $100.95

所用估值方法之间的离散区间,并非经过统计校准的置信区间。

估算方法

分析师目标价:$97.27
现金流折现法(DCF):$97.21
市盈率法(P/E):$51.61
格雷厄姆成长公式:$43.59
盈利能力价值(EPV):$50.50
合理市净率(P/B):$40.68
股息折现模型(戈登模型):数据不足,无法计算
P/FFO(运营资金):$101.79
周期中段收益:$164.55
市销率法(P/S):$468.49
分析师共识:买入 (15B / 9H / 1S)
最近财报超预期:+0.67%

估值指标

市盈率(P/E)

24.48

ROE

12.3%

市净率(P/B)

2.96

P/FCF

16.45

毛利率

31.3%

ROIC

6.8%

盈利能力雷达图

价值创造(经济护城河)

ROIC

6.8%

WACC

7.5%

ROIC − WACC

-0.7 pp

ROIC 与资本成本大致持平:公司仅仅覆盖了资本成本。

基本面分析标准

通过(18)

  • EPS shows upward trend
  • ROIC 6.8%
  • Gross Margin 31.3%
  • P/FCF 16.45
  • P/B Ratio 2.96
  • Debt/Equity ratio
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 12.4%
  • Revenue Growth 5Y 5.4%
  • Analyst Consensus 60% Buy
  • Earnings Surprise avg 3.5%
  • Earnings Quality (OCF/NI) 1.74
  • Share Dilution -4.8%

未通过(9)

  • EPS CAGR 1.29%
  • Price CAGR 3.64%
  • Operating Margin 5.0%
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Fairly valued)
  • PEG Ratio 7.91
  • Net Margin Trend 3.0% vs 3.0%
  • Piotroski F-Score 4/9

不可用(1)

  • Dividend Payout NaN%

Piotroski F-评分

4/9

信号混杂:部分领域需关注

score
criteria

盈利质量

1.74

高质量:盈利有现金流支撑

股权稀释

-4.8%

正在回购股份,对股东友好

机构持股

公司治理

管理团队

姓名职位年龄
Mr. Ronald N. SouthSenior VP & CFO63
Mr. Michael Saul EttingerExecutive VP & COO64
Mr. Mark E. MlotekExecutive VP & Chief Strategic Officer69
Mr. Andrea AlbertiniChief Executive Officer of Global Distribution & Technology55
Mr. Frederick M. LoweryCEO & Director54
Ms. Olga TimoshkinaVP of Corporate Finance & Chief Accounting Officer-
Mr. Christopher PendergastSenior VP & CTO62
Mr. Graham StanleyVP of Investor Relations & Strategic Finance Project Officer-
Ms. Kelly Murphy J.D.Senior VP & General Counsel44
Ms. Christine SheehySenior VP & Chief Human Resources Officer57

审计风险

4

董事会风险

8

薪酬风险

6

股东权利风险

4

第二部分 · 价格与买入时机

这一部分不判断公司是否值得拥有:它帮助你在基本面说服你之后,选择何时买入。包含:技术分析、潜力、历史回撤、Gamma 敞口。

文件

  • 年度报告(10-K)

    对公司业务、财务业绩和风险的年度概述。

    提交日期:2026-02-24

    查看文件
  • 季度报告(10-Q)

    最近三个月财务表现的最新情况。

    提交日期:2026-08-04

    查看文件
  • 临时报告(8-K)

    关于重大事件(如管理层变动或重要公告)的通知。

    提交日期:2026-09-22

    查看文件

via SEC EDGAR

损益历史

via SEC EDGAR

Latest News

Recent headlines for HSIC, sourced from Markets Gazette.

  • 6/11/2026POSITIVE
    This Henry Schein Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

    Henry Schein Inc. (HSIC) has received a bullish upgrade from Wall Street analysts, signaling a potentially positive outlook for the company's stock. While specific details of the upgrade and the analysts' reasoning are not provided in this snippet, such a shift in sentiment typically suggests that analysts foresee improved financial performance, strategic advantages, or favorable market conditions for HSIC. Investors often view analyst upgrades as a catalyst for stock price appreciation, potentially leading to increased buying interest and upward price momentum.

  • 2/24/2026NEUTRAL
    Henry Schein (HSIC) Q4 2025 Earnings Transcript

    Investors in Henry Schein Inc. (HSIC) are poised to analyze the Q4 2025 earnings transcript, released on February 24, 2026. This event is pivotal for understanding the financial performance of the company, a global leader in distributing healthcare products and services to medical and dental practices. The report's analysis will provide crucial details on revenues, earnings per share (EPS), operating margins, and future outlook, which are fundamental elements for assessing the company's health and potential growth trajectories. While specific data is not yet available for direct evaluation, the transcript's release marks a key moment for the market, allowing deeper insight into management's statements and responses to analyst questions, thereby shaping expectations for the upcoming fiscal period and its impact on share value.

via Markets Gazette